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Abstract 
Healthcare systems in low- and middle-income countries (LMICs) face considerable population 
healthcare needs with markedly fewer resources than those in developed countries.  The way in 
which available resources are allocated across competing priorities is crucial in affecting how much 
health is generated overall, who receives healthcare interventions and who goes without.  Cost-
effectiveness analysis (CEA) is one tool that can assist policy-makers in resource allocation.  The 
central concern in CEA is whether the health gains offered by an intervention are large enough 
relative to its costs to warrant adoption.  This requires some notion of the value that must be 
realized by an intervention, which is most frequently represented using a cost-effectiveness 
threshold (CET). 
 
CETs should be based on estimates of the forgone benefit associated with alternative priorities 
which consequently cannot be implemented as a result of the commitment of resources to an 
alternative.  For most health care systems these opportunity costs fall predominantly on health as a 
ƌĞƐƵůƚŽĨĨŝǆĞĚďƵĚŐĞƚƐŽƌĐŽŶƐƚƌĂŝŶƚƐŽŶŚĞĂůƚŚƐǇƐƚĞŵƐ ?Ăďŝůŝties to increase expenditures.  However, 
many CEAs to inform decisions in LMICs have used aspirational expressions of value, such as the 
World Health Organization ?Ɛ (WHO) recommended CETs (of 1-3 times GDP per capita in a country) 
which are not based upon opportunity costs.  In contrast, we estimate CETs for a number of 
countries based upon recent empirical estimates of foregone benefit (from the English NHS) and 
international income elasticities of the value of health.  The resulting CETs are much lower than 
those previously posited by WHO.  There is no intention to provide definitive CETs; rather, the study 
is intended to provoke further research in this area of crucial policy importance and outlines how 
more robust estimates of CETs could be generated. 
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1. Introduction  
Policy-makers in all healthcare systems face difficult choices about which interventions, programmes 
or activities (hereinafter ƌĞĨĞƌƌĞĚƚŽƐŽůĞůǇĂƐ ‘ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ?should be funded from limited 
available resources.  The tools of economic evaluation offer a variety of means to assist policymakers 
in the process of prioritization.  A common approach is that of incremental cost-effectiveness 
analysis (CEA) which is based upon the comparative assessment of costs and health benefits.  CEA 
seeks to identify which interventions offer health benefits large enough relative to costs to warrant 
adoption and those that do not.[1] 
 
Results in CEA are often represented in the form of an incremental cost-effectiveness ratio (ICER); 
the ratio of incremental costs to incremental health benefits of one intervention compared to 
another mutually exclusive alternative ( ?ܿ݋ݏݐݏ  ?݄݈݁ܽݐ݄ܾ݂݁݊݁݅ݐݏൗ ).[1]  Health benefits are often 
ƌĞƉƌĞƐĞŶƚĞĚŝŶƚŚĞĨŽƌŵŽĨƋƵĂůŝƚǇĂĚũƵƐƚĞĚůŝĨĞǇĞĂƌƐ ?Y>zƐ ? ?ĂŶĚƐŽƚŚĞ/ZŐŝǀĞƐƚŚĞ ‘ĐŽƐƚƉĞƌ
QALY gain ? associated with an intervention.  To determine whether an ŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐICER is likely to 
represent a  ‘good buy ? requires comparison to some benchmark of value.  The benchmark most 
frequently used is the cost-effectiveness threshold (CET).  If an ICER<CET, ĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ?Ɛ health 
benefits ĂƌĞĚĞĞŵĞĚůĂƌŐĞĞŶŽƵŐŚŝŶĐŽŵƉĂƌŝƐŽŶƚŽĐŽƐƚƐ ?ŝ ?Ğ ?ŝƚŝƐĚĞĞŵĞĚ ‘ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞ ? ?; but if 
ICER>CET the benefits are insufficient in comparison to costs (i.e. it is not cost-effective). 
 
The choice of CET is, therefore, crucial in determining value from healthcare interventions when 
applying incremental CEA.  A key concept in all economic analysis is ƚŚĂƚŽĨ ‘ŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐ ? ?[2]  
All healthcare systems face resource constraints so if resources are committed to the funding of one 
intervention these are not available to fund and deliver others.  Opportunity costs are the health 
benefits forgone due to the commitment of scarce resources to particular investments, or if 
additional resources are made available, the health that could have been gained by investing these 
resources elsewhere in the healthcare system.  For CEA to be consistent with population health 
improvement there is a need for chosen CETs to reflect opportunity costs.  However, the estimation 
of opportunity costs for different kinds of decisions remains a major challenge. 
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2. Understanding and estimating cost-effectiveness thresholds 
Recent methods research has brought greater clarity as to normative basis for the use of CETs and 
how they can be appropriately estimated so as to improve population health.[3, 4]  A clear 
distinction needs to be made between two related, but separate, concepts of opportunity costs: (i) 
opportunity costs in terms of health forgone  W due to the commitment of limited collective 
healthcare resources to particular interventions; (ii) opportunity costs in terms of forgone 
consumption (the  ‘consumption value of health ? ?ǁŚĞŶadditional costs fall on consumption 
opportunities outside health care rather than on health care expenditure.  The first, (i), can also be 
ƚĞƌŵĞĚƚŚĞ ‘ƐŚĂĚŽǁƉƌŝĐĞŽĨƚŚĞďƵĚŐĞƚĐŽŶƐƚƌĂŝŶƚ ? ? It is an issue of  ‘ĨĂĐƚ ? ?ƌĞƐƵůƚŝŶŐĨƌŽŵůŝŵŝƚƐŝŶƚŚĞ
overall collective budget available for healthcare ŽƌĐŽŶƐƚƌĂŝŶƚƐŽŶŚĞĂůƚŚƐǇƐƚĞŵ ?ƐĂďŝůŝƚŝĞƐƚŽ
increase expenditure.  The second, (ii), is an issue of  ‘ǀĂůƵĞ ?ĂŶĚĚĞƉĞŶĚƐƵƉŽŶŚŽǁŝŶĚŝǀŝĚƵĂůƐǀĂůƵĞ
health as compared to other forms of consumption. 
 
For economic evaluation of an intervention, it is important to consider what type of opportunity 
costs would result from investment in new activities.  If opportunity costs result in the form of health 
forgone (e.g. through displacement of other health generating interventions funded from a 
collective healthcare budget), then the CET should reflect this  W ůĞƚ ?ƐĚĞŶŽƚĞƚŚŝƐ ‘Ŭ ? ?ƚŚĞ ratio of the 
cost reduction associated with displacing interventions to the QALYs lost).  If opportunity costs are in 
terms of other forms of consumption (e.g. if the intervention relies on other sources of funding such 
as out-of-pocket contributions), the CET should reflect the consumption value of health - ůĞƚ ?Ɛ
denote this  ‘ǀ ? ?
 
Observing that an estimate of the consumption value of health is higher than the amount of 
healthcare resource required to improve health (v > k) suggests that the healthcare system is not 
meeting individual preferences, because individuals would be willing to give up more of the 
resources available to them to improve their own health than the healthcare system would require.  
Simply assuming that v is equal to k would be inappropriate since there are good reasons to expect 
v>k not least the welfare losses associated with socially acceptable ways to finance healthcare 
systems (i.e. society would not increase health expenditure to the point where v=k). 
 
For incremental CEA to suitably inform the allocation of healthcare expenditures, for which the 
primarily purpose is generally regarded as being ƚŚĞŐĞŶĞƌĂƚŝŽŶŽĨ ‘ŚĞĂůƚŚ ? from limited collective 
healthcare resources, CETs reflecting the opportunity costs of healthcare spending (k) will always be 
required if there are any restrictions on the growth in health care expenditure.  There are at least 
two ways in which k could be determined. 
 
Firstly, a threshold can be chosen based upon what it is felt a health system should be willing to pay 
for health  W for which distinction can be made between how much individuals would be willing to 
pay to improve health (v: the consumption value of health) and simply aspirational notions of how 
the world should be (or how much other individuals should be willing to spend to improve their 
health, without consideration of other calls on their resources). 
 
Secondly, the relationship between changes in healthcare expenditure and health outcomes can be 
estimated (i.e. the marginal productivity of the healthcare system in generating health) as a direct 
measure of what is likely to be displaced when a cost-escalating intervention is adopted or what 
could be gained elsewhere if cost-savings are made or additional resources are made available. 
 
The first of the approaches tends to dominate in practice in all healthcare systems.  For instance, a 
value of US$50,000 has been commonly applied in the United States.[5]  Similarly, for low and 
middle income countries, the World Health Organization (WHO) has recommended thresholds of 1 
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to 3 times gross domestic product (GDP) per capita for use in low and middle income countries.[6]  
These values  W from the US and from WHO  W are not based upon assessment of health opportunity 
costs resulting from resource constraints.  Instead theǇĐĂŶďĞƐĞĞŶĂƐƐƚĂƚĞŵĞŶƚƐŽĨ ‘ǀĂůƵĞ ? ?ǁŚĂƚŝƚ
is felt health systems should be willing to pay for health gains (the US estimate motivated more by 
ŝŶĚŝǀŝĚƵĂůƐ ?ĞǆƉƌĞƐƐŝŽŶƐŽĨǁŝůůŝŶŐŶĞƐƐƚŽƉĂǇĨŽƌŚĞĂůƚŚŐĂŝŶƐ ?ƚŚĞt,KĂƉƉƌŽĂĐŚďĂƐĞĚŽŶ
aspiration).  However, their use is not necessarily consistent with population health improvement as 
they do not reflect the opportunity cost that is imposed on the health care system.  They can 
therefore be seen as inappropriate measures of k that risk reducing, rather than increasing, 
population health. 
 
The second approach is an empirical means to estimate k based upon assessment of health benefits 
forgone when funding is committed to particular interventions.  Estimating k in this way provides a 
basis for making resource allocation decisions that increase population health.  However, there is a 
paucity of estimates available in any jurisdiction using these approaches.  One notable exception is 
Claxton et al.[4] who used local level programme expenditure data, in a range of disease areas, to 
estimate the relationship between changes in healthcare expenditure and health outcomes in the 
English National Health Service. 
 
By exploiting the variation in expenditure and mortality outcomes, Claxton et al. estimate the 
relationship between changes in spending and mortality while accounting for endogeneity.  With 
additional information about age and gender of the patient population these mortality effects were 
expressed as a cost per life year threshold (£25,241 per life year).  These life year effects were 
adjusted for quality of life with additional information about quality of life norms by age and gender, 
as well as the quality of life impacts of different types of disease.  By using the effect of expenditure 
on the mortality and life year burden of disease as a surrogate for the effects on a more complete 
measure of health burden (i.e. that includes quality of life burden) a cost per QALY threshold was 
estimated of UK£12,936 (US$20,212) per QALY.[4] 
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3. Estimating cost-effectiveness thresholds for other countries 
There is a lack of empirically based estimates of k (based on opportunity costs in terms of health) for 
jurisdictions other than the UK despite growing recognition that such estimates are required to 
suitably inform resource allocation decisions.[7, 8]  The Claxton et al. estimate of k is based upon 
estimates of the marginal productivity of healthcare spending in just one jurisdiction.[4]  In principle, 
a similar approach could be adopted to estimate the relationship between healthcare spending and 
health outcomes internationally, using countries as units of analysis, to determine k in a wide range 
of settings. 
 
To date, however, cross-country evidence on the productivity of healthcare spending has focused on 
ĂŶƐǁĞƌŝŶŐƚŚĞƋƵĞƐƚŝŽŶ “ĚŽĞƐŚĞĂůƚŚĐĂƌĞƐƉĞŶĚŝŶŐŝŵƉƌŽǀĞŚĞĂůƚŚŽƵƚĐŽŵĞƐ ? ?  Recent research 
adjusting for potential reverse causality in this relationship (e.g. governments may spend more when 
health outcomes are worse) suggests that the answer to this question is yes.[9]  However, the 
available literature does not focus on how the effect of healthcare spending on health outcomes 
varies according to the level of healthcare spending or country income.  The analyses available do 
suggest that the marginal productivity of healthcare spending diminishes with healthcare spending 
or country income.[10-12]  This indicates that the threshold should increase with country income or 
healthcare spending as the amount of health displaced by new resource commitments as country 
income / health care spending rises.  However, there is little information about the rate at which this 
increase occurs1.  Understanding this would require careful exploration of the functional form of the 
relationship between healthcare spending and health outcomes. 
 
However, there is a body of literature that estimates v (the consumption value of health) in different 
countries.  Some of this literature is based upon stated preference elicitation of individuals ? 
willingness-to-pay (WTP) for morbidity adjusted life years (e.g. QALYs)[13, 14], but a larger body of 
ǁŽƌŬĞƐƚŝŵĂƚĞƐƚŚĞ ‘ǀĂůƵĞŽĨĂƐƚĂƚŝƐƚŝĐĂůůŝĨĞ ? ?s^> ?from mortality reductions (e.g. through 
estimating compensating differentials for on the job risk exposure in labour markets).[15, 16]  
Moreover, the VSL literature also examines how the VSL varies across jurisdictions as a function of 
national per capita income (i.e. the elasticity of the VSL with respect to income ?ɸ) (see below).  This 
potentially provides information about the income elasticity of v if we can assume that the income 
elasticity of the VSL is equal to the income elasticity of the value of a life year, and this in turn is 
equal to the income elasticity of the value of a morbidity adjusted life year (e.g. QALY).  For this to be 
the case across countries, a VSL must convert to the same number of QALYs across countries (the 
plausibility of this assumption is examined in the Discussion). 
 
Understanding the income elasticity of v across countries of different income levels raises an 
interesting prospect.  If a similar income elasticity of k exists as for v, income elasticities of the VSL 
can be applied to the Claxton et al. estimate of k for the English NHS to provide estimates of k in a 
wide range of jurisdictions.  We follow this approach to provide estimates of k for application in 
different countries based upon their per capita income levels using the cost-effectiveness threshold 
for the NHS, per capita income in the UK and the elasticity of VSL with respect to income.  (Figure 1).  
The approach is based upon two core assumptions: (1) that the discrepancy between v and k is 
constant across countries in percentage terms  ?ŝ ?Ğ ?ƚŚĂƚ ‘ƵŶĚĞƌĨƵŶĚŝŶŐ ?ŽĨŚĞĂůƚŚĐĂƌĞƚŚƌŽƵŐŚ
collectively pooled resources relative to individual preferences over consumption and health is 
                                                          
1
 Typically constant elasticity production functions are modelled. These impose significant constraints on the way the 
threshold can vary with income or health care spending. Namely, values of the elasticity of health with respect to health 
care spending or income must be <1.0 for the threshold to be increasing in health care spending or income. However, 
values of the elasticity <1.0 also imply that the threshold increases at a diminishing rate with health care spending or 
income. 
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Figure 1: Method for inferring country-specific cost-effectiveness thresholds from UK 
threshold 
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4. What is known about the income elasticity of the value of health? 
The relationship between the value of a statistical life (VSL) and per capita income at the level of 
jurisdictions (e.g. of countries) is investigated in a small but emerging literature.[16-18]  The 
literature has evolved out of a longer standing body of work which has examined the relationship 
ďĞƚǁĞĞŶŝŶĐŽŵĞĂŶĚŚĞĂůƚŚǀĂůƵĂƚŝŽŶĂƚƚŚĞůĞǀĞůŽĨŝŶĚŝǀŝĚƵĂůƐ ?ŝ ?Ğ ? ‘ǁŝƚŚŝŶ ?ĐŽƵŶƚƌŝĞƐ ? ?[15, 17] 
 
Of central interest in both these bodies of work (within-group, at the individual level, and between-
group, at the level of jurisdictions) is the income elasticity of the value of health and whether this is 
less than 1 (so health is a necessity good) or greater than 1 (so health is a luxury good); and whether 
the elasticity is likely to change for different levels of income.[17] 
 
Initial research conducted primarily in higher income countries amongst individuals, and most often 
in the United States, suggested elasticities in the range 0.4-0.6.[15, 16]  These estimates came 
mainly from cross-sectional studies looking at wage-risk premiums.  However, the estimates have 
been described as  ‘nonsensical ? when extrapolated to lower income countries since the 
corresponding VSL would be beyond the ranges deemed plausible in such settings.[16] 
 
The methods to estimate income elasticities of VSL have, therefore, been more carefully scrutinized 
in more recent years.  In particular, cross sectional  ? ‘ǁŝƚŚŝŶŐƌŽƵƉ ? ?ĞƐƚŝŵĂƚĞƐĨƌŽŵĞĂƌůŝĞƌƐƚƵĚŝĞƐ
have been contrasted with longitudinal or cohort  ? ‘ďĞƚǁĞĞŶŐƌŽƵƉ ? ?studies (which typically estimate 
elasticities>1; even within countries) and reasons for inconsistencies explored.[16, 17, 19]  For 
instance, Aldy and Smyth (2014) use a life-cycle model applied to US data of the consumption and 
labour supply choices faced by individuals with uncertain life expectancy and wage income to 
explain this discrepancy.[19]  They argue that cross-sectional studies are more likely to capture 
changes in realised income, whereas longitudinal or across cohort studies capture the impact of 
permanent income which is more informative when translating VSL estimates across countries.  
Estimates of elasticity with respect to realised income are lower as realised income is more variable. 
Similarly, Getzen (2000) concludes that ǁŚĞƌĞĂƐ ‘ǁŝƚŚŝŶŐƌŽƵƉ ?ŚĞĂůƚŚŵĂǇďĞĚĞĞŵĞĚĂŶĞĐĞƐƐŝƚǇ ?
ĂŶĂůǇƐĞƐŽĨĞǆƉĞŶĚŝƚƵƌĞƐ ‘ďĞƚǁĞĞŶŐƌŽƵƉ ?ŝŶĚŝĐĂƚĞŝƚŝƐĂůŵŽƐƚĐĞƌƚĂŝŶůǇĂůuxury good at the national 
level.[17] 
 
The recent consensus then is that the income elasticity of VSL to transfer estimates across countries 
should be >1.[16, 18]  We choose to apply a range of elasticities (1.0, 1.5 and 2.0) to reflect 
uncertainty in the literature.  Based upon Milligan et al (2014), a function is also applied of an 
elasticity of 2.5 for countries with gross domestic product (GDP) per capita < US$10,725 (2005 price 
year) purchasing power parity (PPP) and of 0.7 for countries with per capita incomes greater than 
this level2.[18] 
  
                                                          
2
 In line with the recommendations in Milligan et al. 2014 the elasticities from this study are applied to 2013 PPP-adjusted 
GDP, deflated to reflect 2005 international dollars. The resulting threshold values are then inflated to reflect 2013 
international dollars. 
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5. Results: country level estimates of cost-effectiveness thresholds 
The best estimate of the UK CET is £12,936 per QALY (US$18,609 purchasing power parity (PPP) 
adjusted3).  Gross domestic product (GDP) per capita estimates were obtained from the World Bank 
dataset for 2013.4  In line with the literature on the value of a statistical life we apply elasticities to 
countries ? GDP per capita adjusted for purchasing power parity (see for example Milligan 
(2014)).[18]  CETs are reported in 2013 PPP adjusted US dollar values.  Values without PPP 
adjustment are also provided for specific countries5. 
 
Predicted CETs across country income levels are shown in Figure 2 for a range of income elasticities 
for the VSL.  Higher income elasticities imply lower CETs in countries with lower GDP p.c. compared 
to the UK, and higher CETs in countries with higher GDP p.c. compared to the UK.  The impact of 
alternative choices of elasticity is larger as the discrepancy between the GDP of the country of 
interest and UK GDP widens.  Results for a selection of specific countries are shown in Table 1. 
 
 
Figure 2: Predicted cost-effectiveness threshold (k) values by country income 
 
 
 
 
 
 
 
                                                          
3
 This analysis uses the PPP conversion factor: http://data.worldbank.org/indicator/PA.NUS.PPP 
4
 This analysis uses PPP adjusted GDP per capita: http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD 
5
 This analysis uses data on the ratio of the PPP conversion factor to the market exchange rate to remove the PPP 
adjustment but retain the presentation in dollars: http://data.worldbank.org/indicator/PA.NUS.PPPC.RF. Results are also 
presented in comparison to non-PPP adjusted GDP: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. 
$0
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
$70,000
$0 $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000
T
h
re
sh
o
ld
 (
U
S
D
 P
P
P
 a
d
ju
st
ed
/
Q
A
L
Y
)
GDP per capita PPP adjusted (USD)
Constant elasticity = 1.0
Constant elasticity = 1.5
Constant elasticity = 2.0
(ODVWLFLW\ LI *'3LI *'3
8  CHE Research Paper 109 
 
Table 1: Example results for a range of countries and the World Bank income classification cut-offs 
  PPP-adjusted (2013 USD) Actual values (2013 USD) Threshold as 
% GDP Country/classification GDP p.c. Threshold range
+
 GDP p.c. Threshold range
+
 
Malawi 780 9 - 401 
                       
226  3 - 116 1% - 51% 
Indonesia 9,559 1,298 - 4,914 
                     
3,475  472 - 1,786 14% - 51% 
Chile 21,911 6,819 - 13,141 
                   
15,732  4,896 - 9,436 31% - 60% 
Kazakhstan 23,206 7,648 - 13,675 
                   
13,610  4,485 - 8,018 33% - 59% 
United kingdom 36,197 18,609 - 18,609 
                   
41,787  20,223 - 20,223 48% - 48%
#
 
Canada 43,247 21,051 - 26,564 
                   
51,958  25,292 - 31,915 49% - 61% 
United states 53,143 24,283 - 40,112 
                   
53,042  24,283 - 40,112 46% - 75% 
Norway 65,461 28,057 - 60,862 
                 
100,819  43,211 - 93,736 43% - 93% 
Low/middle income* 
                     
1,045  16 - 537 
 
 
Not available 
 
1% - 51% 
Middle/high income* 12,746 2,307 - 9,028 18% - 71% 
* We have assumed Gross National Income per capita to be the same as PPP adjusted GDP. These values relate to the 
income cut-offs for low to middle income and middle to high income countries as defined by the World Bank. 
+ 
Reflects 
range of values obtained when using elasticity estimates of 1.0, 1.5, 2.0 and 2.5 for GDP less than $10,725 and 0.7 for GDP 
greater than $10,725. 
#
 For the UK the World Bank ratio of PPP conversion factor to market exchange rate did not 
correspond to the ratio of reported actual GDP to reported PPP-adjusted GDP. The threshold as a % GDP value for the UK 
therefore depends on whether PPP-adjusted or actual data are used (51% and 48% respectively). 
 
The estimated CETs are substantially lower than those currently used by decision-making agencies 
and international organizations.  Compared to a threshold of US$50,000 per QALY that has been 
conventionally applied in the US, our approach estimates a CET in the range US$24,283-US$40,112 
per QALY.  Even more starkly, in comparison to thresholds of 1-3 times GDP per capita 
recommended by the WHO, the upper bounds of our estimates indicate values of 51% GDP p.c. for 
countries classified as low income and 71% GDP p.c. for those classified as middle income. 
US dollar CET values with and without PPP adjustment are provided in the appendix for all countries 
for which data was available from the World Bank database for 2013.  Values without adjustment for 
PPP can be converted to local currency using standard exchange rates. 
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6. Discussion 
Policymakers in all countries face difficult decisions about how to allocate scarce healthcare 
resources to maximize health gains for their populations.  Cost-effectiveness analysis offers a means 
by which to compare the costs and health gains from alternative interventions as a basis to inform 
investment.  For the results of CEA to align with population health improvement requires that health 
gains from recommended interventions exceed the opportunity costs of health forgone when 
resources are committed to those interventions.  The health opportunity costs should be reflected in 
the cost effectiveness threshold (k).  Health opportunity costs can be contrasted to the consumption 
value of health (v) based upon individuals ? expressions of the value of health gains. 
 
In this paper we provide estimates of cost-effectiveness thresholds  ?ƚŚĞ ‘Ŭ ?Ɛ ?in a number of 
countries based upon assessment of the likely marginal productivity of their healthcare systems.  
This has required (i) an estimate of the marginal productivity in the English NHS from Claxton et al.; 
(ii) estimates of the GDP p.c. of the UK and other countries of interest; and (iii) estimates of the 
elasticity of the value of health  ? ‘ǀ ? ? with respect to countries ? per capita income (proxied by income 
elasticities of the value of a statistical life (VSL)).  We estimate thresholds far lower than those 
conventionally applied; which implies that CEAs are likely to be recommending interventions which 
lead to reductions in population health. 
 
The results presented rely upon some core assumptions if they are to be reasonable extrapolations 
to reflect the marginal productivity of other (non-UK) healthcare systems: (1) that the discrepancy 
between the consumption value of health (v) and cost-effectiveness threshold for health (k) is 
constant in percentage terms across countries ? ? ? ?ƚŚĂƚƚŚĞh<ŝƐ ‘ƚǇƉŝĐĂů ? of other countries with 
respect to the values of v and k; and (3) that the income elasticity of VSL equals the income elasticity 
of the consumption value of a QALY. 
 
Two reasons why the proportional discrepancy between k and v may differ across country income 
levels include: (i) non-constant ratios between individual and societal valuations of health (e.g. due 
to differences in understanding of health production functions and the trade-off associated with an 
implied v) ; (ii) constraints on the size of the health care budget differing for reasons other than 
societal valuations of healthcare spending (e.g. differences in tax generating abilities due to 
technical/administrative reasons).  The ratio of v/k represents the value of collective compared to 
private resource or the shadow price of public expenditure. 
 
dŚĞĂƐƐƵŵƉƚŝŽŶƚŚĂƚƚŚĞh<ŝƐ ‘ƚǇƉŝĐĂů ? of countries with respect to health production possibilities in 
part relies upon the UK healthcare system (the NHS) being of  ‘typical ? efficiency in converting health 
sector resources to health gains for a country of its income level.  There is some limited evidence the 
UK NHS may incur less waste than other health sectors (as indicated for example by relatively high 
use of generic drugs [20]) or be more efficient due to bodies such as the National Institute for Health 
and Care Excellence.  If the UK is more productive, this means our analysis over-estimates the 
marginal productivity of other healthcare systems and under-estimates k.  However, if the UK is less 
wasteful than other countries, the UK estimate of k can be considered relevant to a higher income 
level than UK GDP (as waste is simply lost income), this suggests our analysis may over-estimate k.  
Depending on the magnitude of these effects our analysis may over or under-estimate the marginal 
productivity of other healthcare systems and under- or over-estimate k.  However, if this were the 
case, it also implies that perhaps other countries could seek efficiency gains by reassessing what 
interventions they currently provide and at what cost, rather than evaluating new interventions 
more leniently. 
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For the elasticity of the VSL to equal the elasticity of the consumption value of health (v), a statistical 
life should provide the same units of morbidity-adjusted health (e.g. QALYs) across countries.  This 
could be questioned if lives-saved were expected to generate very different remaining morbidity-
adjusted life expectancies.  Although life expectancy at birth varies considerably across countries, 
remaining life expectancy differs much less due to differences in age demographics (e.g. Hammitt 
and Robinson, 2011, find remaining life expectancies between 34 and 45 years in countries with 
widely varying per capita incomes as a result of much older populations in countries with higher life 
expectancies at birth[16]).  Again, although quality of life is likely to be increasing in income, older 
populations would also be expected to have higher levels of morbidity so differences in QALYs 
gained may also be small. 
 
Therefore, although our results are embedded with many assumptions, it is not immediately clear 
whether these are likely to lead to our estimates of k being positively or negatively biased. 
 
These results should, however, only be regarded as a first attempt to inform this area of crucial 
policy importance.  The estimates can be used to inform policy decisions, particularly in the absence 
of other estimates based upon an assessment of health opportunity costs; but they should be 
applied cautiously.  They can in some ways be regarded as a provocation to inspire more research.  
What research could then be undertaken to better inform thresholds for use within countries? 
 
Aside from the relatively elaborate analysis of Claxton et al. being repeated in every country, which 
would likely not be possible due to data constraints in many jurisdictions, econometric analyses of 
policy reforms and other natural experiments could inform the marginal productivity of health 
sectors.  Another approach could be to explore the cost-effectiveness of interventions currently 
provided within a country and those falling outside of the budget envelope.  In this way, 
policymĂŬĞƌƐĐĂŶƵŶĚĞƌŐŽĂƉƌŽĐĞƐƐŽĨ ‘threshold seeking ?[21] and become more informed about k 
as the number of CEAs in their jurisdiction increases.  One example of a study using an approach 
similar to this is from Malawi - the country with the lowest per capita income from those presented 
in this paper  W and suggests a threshold of no more (and perhaps less) than US$150 in that 
country.[22]  Encouragingly, this is slightly above the range (US$3-US$116) that we estimate. 
 
As has already been highlighted, an analysis of cross-country data with countries as units of analysis 
could be used to inform international estimates of marginal productivity of healthcare.  Moreno-
Serra and Smith (2014), adopting an approach similar to this but focused on mortality, estimate a 
marginal cost of only $145 per life year saved from public healthcare expenditure in a typical low 
and middle income country.[10]  Another alternative could be a hybrid-type approach whereby a 
small number of within-country empirical estimates of thresholds are produced which are then 
extrapolated across income levels to provide estimates for a greater number of countries. 
 
All such analyses are likely to have important roles in the quest for greater allocative efficiency, 
leading to overall population health gains, in health sectors across the world. 
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7. Conclusion 
The cost-effectiveness thresholds presented in this paper are much lower than those previously 
applied in many countries (e.g. using WHO recommended cost-effectiveness thresholds of 1-3 times 
GDP per capita).  The results have potentially profound consequences for resource allocation.  It is 
hoped they will provoke further research on this topic. 
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Appendix: All country values 
The table below presents the PPP-adjusted and non-adjusted range of threshold values for each 
country for which PPP-adjusted GDP was reported in the World Bank database.  In some cases data 
was not available to remove the PPP-adjustment and only PPP-adjusted threshold values are 
reported.  
Country 
Cost-effectiveness threshold range 
 (USD, PPP adjusted) (actual USD) 
Afghanistan 56 - 1,023 19 - 349 
Albania 1,563 - 5,816 702 - 2,612 
Algeria 2,514 - 9,300 1,012 - 3,743 
Angola 807 - 3,875 603 - 2,897 
Antigua and Barbuda 6,250 - 12,750 3,965 - 8,090 
Armenia 858 - 3,997 387 - 1,801 
Australia 21,153 - 26,938 32,771 - 41,732 
Austria 21,355 - 27,684 23,727 - 30,759 
Azerbaijan 4,172 - 11,085 1,901 - 5,051 
Bahrain 21,245 - 27,277 11,962 - 15,358 
Bangladesh 93 - 1,315 30 - 427 
Belarus 4,407 - 11,297 1,895 - 4,857 
Belgium 20,060 - 23,111 22,570 - 26,003 
Belize 1,012 - 4,340 584 - 2,503 
Benin 46 - 921 20 - 414 
Bhutan 835 - 3,943 267 - 1,258 
Bolivia 534 - 3,151 250 - 1,474 
Bosnia and Herzegovina 1,318 - 4,952 644 - 2,421 
Botswana 3,490 - 10,419 1,621 - 4,839 
Brazil 3,210 - 10,122 2,393 - 7,544 
Brunei Darussalam 29,901 - 73,137 16,065 - 39,294 
Bulgaria 3,609 - 10,541 1,720 - 5,025 
Burkina Faso 38 - 840 17 - 379 
Burundi 8 - 396 3 - 137 
Cabo Verde 584 - 3,297 343 - 1,935 
Cambodia 131 - 1,564 44 - 518 
Cameroon 104 - 1,394 49 - 654 
Canada 21,051 - 26,564 25,292 - 31,915 
Central African Republic 5 - 310 3 - 171 
Chad 61 - 1,070 31 - 540 
Chile 6,819 - 13,141 4,896 - 9,436 
China 2,013 - 7,957 1,151 - 4,550 
Colombia 2,174 - 8,754 1,370 - 5,518 
Comoros 35 - 801 19 - 452 
Congo, Dem. Rep. 8 - 384 5 - 230 
Congo, Rep. 489 - 3,016 264 - 1,628 
Costa Rica 2,733 - 9,574 2,006 - 7,027 
Country-level cost-effectiveness thresholds: initial estimates and the need for further research  15 
 
Country 
Cost-effectiveness threshold range 
 (USD, PPP adjusted) (actual USD) 
Cote d'Ivoire 129 - 1,548 61 - 737 
Croatia 6,206 - 12,720 3,953 - 8,101 
Cyprus 12,318 - 16,130 11,020 - 14,430 
Czech Republic 10,620 - 15,322 7,325 - 10,569 
Denmark 20,888 - 25,974 28,767 - 35,771 
Djibouti 128 - 1,541 71 - 857 
Dominica 1,429 - 5,205 991 - 3,611 
Dominican Republic 1,943 - 7,618 937 - 3,675 
Ecuador 1,557 - 5,788 858 - 3,191 
Egypt, Arab Rep. 1,745 - 6,669 522 - 1,993 
El Salvador 856 - 3,991 422 - 1,967 
Equatorial Guinea 16,150 - 17,717 9,843 - 10,798 
Eritrea 20 - 615 9 - 280 
Estonia 8,912 - 14,418 6,574 - 10,636 
Ethiopia 26 - 696 10 - 255 
Fiji 897 - 4,086 507 - 2,307 
Finland 19,334 - 20,781 23,867 - 25,653 
France 18,861 - 19,347 21,168 - 21,713 
Gabon 5,268 - 12,018 3,164 - 7,218 
Gambia, The 39 - 857 12 - 252 
Georgia 729 - 3,683 366 - 1,850 
Germany 21,080 - 26,668 21,933 - 27,747 
Ghana 224 - 2,043 104 - 951 
Greece 9,345 - 14,658 7,982 - 12,520 
Grenada 1,878 - 7,302 1,272 - 4,948 
Guatemala 756 - 3,750 360 - 1,788 
Guinea 22 - 645 9 - 269 
Guinea-Bissau 22 - 639 9 - 256 
Guyana 610 - 3,368 348 - 1,924 
Haiti 41 - 875 20 - 421 
Honduras 299 - 2,360 149 - 1,177 
Hong Kong SAR, China 24,302 - 40,202 17,409 - 28,801 
Hungary 7,434 - 13,540 4,268 - 7,773 
Iceland 19,942 - 22,720 22,567 - 25,712 
India 416 - 2,781 115 - 770 
Indonesia 1,298 - 4,914 472 - 1,786 
Iran, Islamic Rep. 3,450 - 10,378 1,054 - 3,171 
Iraq 3,276 - 10,194 1,504 - 4,679 
Ireland 21,071 - 26,634 23,063 - 29,153 
Israel 15,243 - 17,366 16,821 - 19,163 
Italy 16,712 - 17,928 16,867 - 18,094 
Jamaica 1,122 - 4,570 668 - 2,719 
Japan 18,651 - 18,731 19,769 - 19,854 
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Country 
Cost-effectiveness threshold range 
 (USD, PPP adjusted) (actual USD) 
Jordan 1,971 - 7,757 872 - 3,432 
Kazakhstan 7,648 - 13,675 4,485 - 8,018 
Kenya 73 - 1,164 32 - 519 
Kiribati 49 - 954 43 - 848 
Korea, Rep. 15,598 - 17,505 12,227 - 13,722 
Kosovo 1,085 - 4,493 473 - 1,961 
Kyrgyz Republic 147 - 1,651 58 - 649 
Lao PDR 329 - 2,474 113 - 852 
Latvia 7,532 - 13,602 5,133 - 9,270 
Lebanon 4,187 - 11,098 2,420 - 6,416 
Lesotho 95 - 1,329 41 - 581 
Liberia 11 - 451 6 - 234 
Libya 6,503 - 12,927 3,697 - 7,349 
Lithuania 9,175 - 14,565 5,598 - 8,886 
Luxembourg 35,195 - 117,072 43,092 - 143,342 
Macao SAR, China 48,116 - 288,671 30,832 - 184,977 
Macedonia, FYR 1,978 - 7,791 824 - 3,246 
Madagascar 28 - 717 9 - 235 
Malawi 9 - 401 3 - 116 
Malaysia 7,709 - 13,712 3,481 - 6,192 
Maldives 1,929 - 7,550 1,103 - 4,318 
Mali 38 - 844 17 - 368 
Malta 12,965 - 16,419 10,138 - 12,838 
Marshall Islands 196 - 1,908 182 - 1,774 
Mauritania 131 - 1,564 46 - 550 
Mauritius 4,202 - 11,112 2,248 - 5,945 
Mexico 3,850 - 10,780 2,410 - 6,749 
Micronesia, Fed. Sts. 180 - 1,829 162 - 1,646 
Moldova 310 - 2,400 148 - 1,151 
Mongolia 1,264 - 4,849 543 - 2,085 
Montenegro 2,912 - 9,786 1,464 - 4,921 
Morocco 736 - 3,702 316 - 1,590 
Mozambique 16 - 537 8 - 294 
Namibia 1,332 - 4,979 791 - 2,958 
Nepal 72 - 1,154 22 - 357 
Netherlands 21,104 - 26,757 23,153 - 29,354 
New Zealand 17,226 - 18,117 20,555 - 21,619 
Nicaragua 297 - 2,350 118 - 937 
Niger 12 - 469 5 - 213 
Nigeria 446 - 2,880 239 - 1,545 
Norway 28,057 - 60,862 43,211 - 93,736 
Oman 21,322 - 27,562 
 Pakistan 314 - 2,416 87 - 669 
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Country 
Cost-effectiveness threshold range 
 (USD, PPP adjusted) (actual USD) 
Palau 3,235 - 10,149 2,531 - 7,940 
Panama 5,352 - 12,083 3,042 - 6,869 
Papua New Guinea 92 - 1,305 75 - 1,073 
Paraguay 919 - 4,135 484 - 2,179 
Peru 1,969 - 7,747 1,114 - 4,383 
Philippines 606 - 3,358 256 - 1,421 
Poland 7,694 - 13,703 4,440 - 7,908 
Portugal 9,527 - 14,756 7,738 - 11,985 
Puerto Rico 17,145 - 18,088 14,075 - 14,849 
Qatar 45,558 - 246,565 31,105 - 168,345 
Romania 4,932 - 11,746 2,467 - 5,875 
Russian Federation 8,263 - 14,046 5,007 - 8,511 
Rwanda 30 - 746 13 - 323 
Samoa 363 - 2,598 265 - 1,897 
Sao Tome and Principe 125 - 1,527 68 - 827 
Saudi Arabia 24,484 - 41,080 11,799 - 19,797 
Senegal 73 - 1,166 34 - 544 
Serbia 2,175 - 8,760 1,061 - 4,275 
Seychelles 8,310 - 14,074 5,470 - 9,265 
Sierra Leone 53 - 990 23 - 435 
Singapore 31,889 - 88,068 22,342 - 61,701 
Slovak Republic 9,686 - 14,841 6,561 - 10,053 
Slovenia 11,374 - 15,690 9,135 - 12,603 
Solomon Islands 61 - 1,063 57 - 1,004 
South Africa 2,221 - 8,909 1,175 - 4,714 
South Sudan 77 - 1,198 40 - 617 
Spain 14,638 - 17,124 13,277 - 15,531 
Sri Lanka 1,346 - 5,005 453 - 1,686 
St. Kitts and Nevis 6,222 - 12,731 4,110 - 8,409 
St. Lucia 1,584 - 5,914 1,107 - 4,133 
St. Vincent and the Grenadines 1,615 - 6,058 998 - 3,746 
Sudan 162 - 1,734 84 - 901 
Suriname 3,740 - 10,672 2,286 - 6,525 
Swaziland 634 - 3,436 288 - 1,559 
Sweden 21,148 - 26,917 28,306 - 36,028 
Switzerland 24,450 - 40,914 36,661 - 61,348 
Tajikistan 90 - 1,291 37 - 533 
Tanzania 45 - 912 18 - 357 
Thailand 2,941 - 9,820 1,181 - 3,943 
Timor-Leste 71 - 1,153 
 Togo 27 - 715 13 - 327 
Tonga 399 - 2,726 333 - 2,275 
Trinidad and Tobago 13,159 - 16,503 7,941 - 9,959 
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Country 
Cost-effectiveness threshold range 
 (USD, PPP adjusted) (actual USD) 
Tunisia 1,747 - 6,680 678 - 2,592 
Turkey 5,114 - 11,895 2,950 - 6,861 
Turkmenistan 2,784 - 9,635 1,588 - 5,495 
Tuvalu 188 - 1,870 200 - 1,991 
Uganda 28 - 725 11 - 293 
Ukraine 1,097 - 4,518 487 - 2,005 
United Kingdom 18,609 - 18,609 20,223 - 20,223 
United States 24,283 - 40,112 24,283 - 40,112 
Uruguay 5,450 - 12,160 4,548 - 10,147 
Uzbekistan 379 - 2,656 138 - 965 
Vanuatu 127 - 1,538 139 - 1,685 
Venezuela, RB 4,701 - 11,553 3,724 - 9,151 
Vietnam 398 - 2,721 144 - 982 
Yemen, Rep. 223 - 2,035 83 - 757 
Zambia 144 - 1,635 68 - 768 
Zimbabwe 41 - 874 21 - 455 
 
